Prime Medicine, Inc.
Ticker: PRME
| Insider | Title |
|---|---|
| 2019 Gp, L.l.c. Gv | 10% or greater ownership |
| 2019 Gp, L.p. Gv | 10% or greater ownership |
| 2019, L.p. Gv | 10% or greater ownership |
| 2021 Gp, L.l.c. Gv | 10% or greater ownership |
| 2021 Gp, L.p. Gv | 10% or greater ownership |
| 2021, L.p. Gv | 10% or greater ownership |
| Allan Reine | Chief Financial Officer |
| Ann L. Lee | Chief Technical Officer |
| Carman Alenson | See Remarks |
| David P Schenkein | Director |
| David R. Liu | 10% or greater ownership |
| Inc. Alphabet | 10% or greater ownership |
| Jeffrey D Marrazzo | Director |
| Jeremy Duffield | Chief Scientific Officer |
| Kaye I Foster-cheek | Director |
| Keith Crandell | 10% or greater ownership |
| Keith Michael Gottesdiener | See Remarks, Director |
| Kristina Burow | 10% or greater ownership |
| Llc Fmr | See Remark 1 |
| Meredith Goldwasser | SVP, Strategy Corporate Ops. |
| Michael Aaron Kelly | Director |
| Richard Brudnick | Chief Business Officer |
| Robert Nelsen | Director, 10% or greater ownership |
| Steven Gillis | 10% or greater ownership |
| Thomas Cahill | Director |
| Venture Fund X Overage, L.p. Arch | 10% or greater ownership |
| Venture Fund X, L.p. Arch | 10% or greater ownership |
| Venture Fund Xii, L.p. Arch | 10% or greater ownership |
| Venture Partners X Overage, L.p. Arch | 10% or greater ownership |
| Venture Partners X, L.p. Arch | 10% or greater ownership |
| Venture Partners X, Llc Arch | 10% or greater ownership |
| Venture Partners Xii, L.p. Arch | 10% or greater ownership |
| Venture Partners Xii, Llc Arch | 10% or greater ownership |
| Wendy Chung | Director |